Final 3-Year Outcome of a Randomized Trial Comparing Second-Generation Drug-Eluting Stents Using Either Biodegradable Polymer or Durable Polymer

2015 ◽  
Vol 8 (10) ◽  
Author(s):  
Masahiro Natsuaki ◽  
Ken Kozuma ◽  
Takeshi Morimoto ◽  
Kazushige Kadota ◽  
Toshiya Muramatsu ◽  
...  
Keyword(s):  
Randomized Trial ◽  
Biodegradable Polymer ◽  
Second Generation ◽  
Drug Eluting Stents ◽  
Durable Polymer ◽  
Drug Eluting

scholarly journals Ultrathin-strut biodegradable polymer versus durable polymer drug-eluting stents: a meta-analysis

Open Heart ◽  
2020 ◽  
Vol 7 (2) ◽  
pp. e001394 ◽  
Author(s):  
Mohammad Riashad Monjur ◽  
Christian F Said ◽  
Paul Bamford ◽  
Michael Parkinson ◽  
Richard Szirt ◽  
...  
Keyword(s):  
Biodegradable Polymer ◽  
Cardiac Death ◽  
Primary Outcome ◽  
Second Generation ◽  
Meta Analysis ◽  
Target Lesion ◽  
Drug Eluting Stents ◽  
Durable Polymer ◽  
Drug Eluting

ObjectivesDetermine whether an ultrathin biodegradable polymer sirolimus-eluting stent (‘Orsiro’—BP-SES) has clinical benefits over second-generation durable polymer drug-eluting stents (DP-DES).MethodsWe conducted a prospective systematic review and meta-analysis of randomised clinical trials comparing Orsiro BP-SES against DP-DES (PROSPERO Registration: CRD42019147136). The primary outcome was target lesion failure (TLF): composite of cardiac death, target vessel myocardial infarction (TVMI) and clinically indicated target lesion revascularisation (TLR)) evaluated at the longest available follow-up.ResultsNine trials randomised 11 302 patients to either Orsiro BP-SES or DP-DES. At mean weighted follow-up of 2.8 years, the primary outcome (TLF) occurred in 501 of 6089 (8.2%) participants with BP-SES compared with 495 of 5213 (9.5%) participants with DP-DES. This equates to an absolute risk reduction of 1.3% in TLF in favour of Orsiro BP-SES (OR 0.82; 95% CI 0.69 to 0.98; p=0.03). This was driven by a reduction in TVMI (OR 0.80; 95% CI 0.65 to 0.98; p=0.03). There were no significant differences in other clinical endpoints: cardiac death, TLR and stent thrombosis.ConclusionThe Orsiro BP-SES shows promising clinical outcomes in patients undergoing percutaneous coronary intervention compared with contemporary second-generation DES at a short to medium term follow-up. More research is warranted to evaluate performance over a longer follow-up period and in different clinical and lesion subsets.

scholarly journals Two-Year Outcome of a Randomized Trial Comparing Second-Generation Drug-Eluting Stents Using Biodegradable or Durable Polymer

JAMA ◽  
2014 ◽  
Vol 311 (20) ◽  
pp. 2125 ◽  
Author(s):  
Masahiro Natsuaki ◽  
Ken Kozuma ◽  
Takeshi Morimoto ◽  
Hiroki Shiomi ◽  
Takeshi Kimura
Keyword(s):  
Randomized Trial ◽  
Second Generation ◽  
Drug Eluting Stents ◽  
Durable Polymer ◽  
Drug Eluting
Sign in / Sign up

Export Citation Format

Share Document